Medexus Pharmaceuticals (TSE:MDP) Lowered to “Hold” Rating by Stifel Canada

Medexus Pharmaceuticals (TSE:MDP) was downgraded by analysts at Stifel Canada from a “strong-buy” rating to a “hold” rating in a report issued on Thursday,Zacks.com reports.

Other equities analysts have also issued research reports about the company. Ventum Financial increased their target price on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a “buy” rating in a research note on Thursday, January 30th. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Stifel Nicolaus downgraded Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price target for the company from C$6.00 to C$3.45 in a research note on Friday. Leede Financial raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, January 22nd. Finally, Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, Medexus Pharmaceuticals has an average rating of “Buy” and a consensus price target of C$5.49.

Medexus Pharmaceuticals Price Performance

MDP opened at C$3.21 on Thursday. The stock has a market capitalization of C$78.74 million, a P/E ratio of 64.20 and a beta of 1.96. The company’s 50 day simple moving average is C$3.53 and its 200-day simple moving average is C$2.82. Medexus Pharmaceuticals has a one year low of C$1.47 and a one year high of C$5.56.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.